Virtual Library
Start Your Search
Saoirse Daly
Author of
-
+
EP1.06 - Mesothelioma (ID 196)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Mesothelioma
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.06-08 - A Retrospective Analysis on Sarcomatoid Mesothelioma to Identify If Chemotherapy Provides Greater Overall Survival Compared to BSC (Now Available) (ID 1229)
08:00 - 18:00 | Author(s): Saoirse Daly
- Abstract
Background
Sarcomatoid is the least common, but most aggressive type of mesothelioma (1) accounting for approximately 11% of all malignant pleural mesothelioma (MPM) (2). However, unlike lung cancer which has different treatment depending on histology, Mesothelioma has the same treatment, regardless of cell type (3, 4). Current data suggests patients with Sarcomatoid Mesothelioma have an average of 5.3 months survival from diagnosis. (5).
Method
Method
A retrospective analysis was undertaken on 9 Sarcomatoid Mesothelioma patients diagnosed and treated from March 2017 to November 2018.
The aim of the audit was to identify if patients who received chemotherapy had better overall survival when compared to those patients’ who received best supportive care (BSC).
All of the 9 patients were PS 0/1 at time of diagnosis.
5 patients had platinum doublet chemotherapy
4 patients had best supportive care partly due to age and concerns of the patient about impact of chemotherapy on quality of life.
Result
2 patients who received chemotherapy died within 8 months of diagnosis.
2 patients who had BSC died within 5 months of diagnosis.
1 patient had 1 line of chemotherapy and then on PD recruited to PROMISE Trial and received Pembrolizamab. Still on treatment at C20.
3 patients who had chemotherapy are still alive on average 1yr 6 months post diagnosis with continuing stable disease.
3 of the patients who had first line chemotherapy went on to receive 2nd line chemotherapy either in or out of a clinical trial.
2 patients BSC still alive with average 6 months progression free survival.
Conclusion
The results do suggest that patients who have chemotherapy do have an OS benefit when compared to those with BSC only. Overall patients tolerated chemotherapy well and have gone on to either receive second line oral Vinorelbine or be recruited into a clinical trial. Due to small numbers of patients it would be good to undertake a formal research study in multiple centres to recruit larger numbers of patients to assess if these results are mirrored nationally. It would also be of interest to identify if Sarcomatoid patients are routinely offered chemotherapy as first line treatment or whether the majority of patients are advised to accept BSC only.
